Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.35 |
| ▸ | FPR2 | P25090 | 3/20 | 0.34 |
| ▸ | PROKR1 | Q8TCW9 | 3/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6689767 | 1.00 | SIGMAR1 (0.39) | SIGMAR1SLC6A4SLC6A2SLC6A3HRH3 | |
| SCHEMBL5331649 | 0.84 | SIGMAR1 (0.38) | SIGMAR1SLC6A4SLC6A2SLC6A3FPR2 | |
| SCHEMBL5333626 | 0.83 | SIGMAR1 (0.45) | SIGMAR1SLC6A4SLC6A2SLC6A3HRH3 | |
| SCHEMBL6636548 | 0.83 | SIGMAR1 (0.45) | SIGMAR1SLC6A4SLC6A2SLC6A3HRH3 | |
| Bromide SCHEMBL7255866 | 0.83 | SIGMAR1 (0.37) | SIGMAR1SLC6A4SLC6A2SLC6A3FPR2 | |
| Hydrochloric Acid SCHEMBL5335584 | 0.83 | SIGMAR1 (0.40) | SIGMAR1SLC6A4SLC6A2SLC6A3FPR2 | |
| Hydrochloric Acid SCHEMBL5335577 | 0.83 | SIGMAR1 (0.40) | SIGMAR1SLC6A4SLC6A2SLC6A3FPR2 | |
| SCHEMBL5345803 | 0.80 | GRIN1 (0.39) | SLC6A4SLC6A2SLC6A3HTR2CKCNH2 | |
| SCHEMBL6929073 | 0.78 | HRH3 (0.49) | SIGMAR1SLC6A4SLC6A2SLC6A3HRH3 | |
| SCHEMBL5222212 | 0.74 | SLC6A4 (0.40) | SIGMAR1SLC6A4SLC6A2SLC6A3FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7288537-B2 | Azetidine derivatives as CCR-3 receptor antagonists | NOVARTIS AG (CH) | 2007-10-30 | — | — | US | disclosed |
| US-20050222118-A1 | Azetidine derivatives as ccr-3 receptor antagonists | NOVARTIS AG (CH) | 2005-10-06 | — | — | US | disclosed |
| EP-1487435-A1 | AZETIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003077907-A1 | AZETIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222118-A1 | Azetidine derivatives as ccr-3 receptor antagonists | CCR3, CCR1, CCR9 | SIGMAR1 412/4885SLC6A4 1121/4885SLC6A2 1453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.